Disruptive technologies for rapid detection of renal transplant rejection

快速检测肾移植排斥反应的颠覆性技术

• 批准号: EP/Y036328/1
• 负责人: Marc Vendrell
• 金额: $ 16.19万
• 依托单位: University of Edinburgh
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2024
• 资助国家: 英国
• 起止时间: 2024 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=EP%2FY036328%2F1
• 关键词: Disruptive; technologies; rapid; detection; renal

Kidney transplantation is the most effective treatment for end-stage kidney failure, which affects over 0.5 million people in the EU; however, 1 in 3 patients may experience acute rejection within the first year of receiving a transplant. Early detection is critical to maximize graft function and improve the quality of life for patients with transplants. Currently, renal transplant monitoring is performed with invasive biopsies or with tests that cannot specifically report on acute transplant rejection. There is a need for noninvasive technologies that can rapidly measure acute organ rejection and monitor disease progression and response to therapy. This unmet patient need drives the development of the project RENO.The ERC CoG project DYNAFLUORS delivered the first fluorescent chemical toolbox for imaging immune cell activity. After organ transplantation, the activity of immune cells is indicative on how patients respond to the transplanted organ. Granzyme B is a protein secreted by over-activated immune cells during acute transplant rejection, with high levels of granzyme B in urine correlating to early stages of kidney rejection and with disease severity. We propose to develop a simple test to measure active granzyme B in urine in real time. This test will enable early identification of acute rejection, reduce the need for invasive biopsies, and encourage prompt treatment to prolong the life of a renal transplant for patients.Funding for this project will allow us to: 1) commercialize our fluorescent reagents for biomedical research through licensing with industry, and 2) establish the foundations for point-of-care technologies to measure granzyme B activity in the urine of patients that have undergone renal transplantation. This project will be guided by input from existing and new industrial and clinical partners, and will create opportunities for accelerating the research, early detection and effective treatment of kidney rejection.

肾脏移植是终末期肾衰竭的最有效治疗方法，该治疗局影响了欧盟超过50万人；但是，三分之一的患者可能会在接受移植的第一年内遭受急性排斥。早期检测对于最大化移植功能并改善移植患者的生活质量至关重要。当前，使用侵入性活检或无法专门报告急性移植排斥反应的测试进行肾移植监测。需要非侵入性技术，这些技术可以快速测量急性器官排斥并监测疾病的进展和对治疗的反应。这种未满足的患者需要驱动Reno项目的开发。ERCCOG项目DynaFluor提供了第一个用于成像免疫细胞活性的荧光化学工具箱。器官移植后，免疫细胞的活性指示患者对移植器官的反应。 Granzyme B是一种在急性移植排斥期间被过度激活的免疫细胞分泌的蛋白质，尿液中的高水平颗粒酶B与肾脏排斥的早期阶段以及疾病严重程度相关。我们建议开发一个简单的测试，以实时测量尿液中的活性颗粒。 This test will enable early identification of acute rejection, reduce the need for invasive biopsies, and encourage prompt treatment to prolong the life of a renal transplant for patients.Funding for this project will allow us to: 1) commercialize our fluorescent reagents for biomedical research through licensing with industry, and 2) establish the foundations for point-of-care technologies to measure granzyme B activity in the urine of patients that have undergone renal移植。该项目将以现有和新的工业和临床合作伙伴的意见为指导，并将为加速研究，早期发现和有效治疗肾脏排斥而创造机会。